SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Tibotec Pharmaceuticals Ltd to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at American Association for Study of Liver Diseases